Mark Ragosa - Apr 26, 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Apr 26, 2025
Transactions value $
-$10,234
Form type
4
Date filed
4/29/2025, 04:34 PM
Previous filing
Apr 9, 2025
Next filing
May 1, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +990 +3.74% 27.5K Apr 26, 2025 Direct F1
transaction KNSA Class A Ordinary Share Tax liability -$10.2K -479 -1.74% $21.37 27K Apr 26, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -990 -100% $0.00 0 Apr 26, 2025 Class A Ordinary Share 990 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021.